Skip to main content

Erythrocouperose Associated With Pityriasis Folliculorum of the Face

0
Pipeline Programs
1
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Pierre Fabre
Pierre FabreFrance - Aignan
1 program
RV5026B - ET1732 - Period 1N/A1 trial
Active Trials
NCT06824870Terminated28Est. Feb 2025

Trial Timeline

Clinical trial activity over time

2023
2024
2025
2026
Pierre FabreRV5026B - ET1732 - Period 1

Clinical Trials (1)

Total enrollment: 28 patients across 1 trials

NCT06824870Pierre FabreRV5026B - ET1732 - Period 1

Exploratory Study Evaluating the Effects of Dermo-cosmetic RV5026B Applied for 2 Months in Adults With Erythrocouperosis

Start: Oct 2023Est. completion: Feb 202528 patients
N/ATerminated

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.